Kang Sun

The MOE Key Laboratory Of Biosystems Homeostasis & Protection, Zhejiang Provincial Key Laboratory For Cancer Molecular Cell Biology
Hangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

CD160+ intraepithelial lymphocytes and CCRL2+ macrophages drive differential repair in cardiac and liver injuries.

CD160+ intraepithelial lymphocytes and CCRL2+ macrophages drive differential repair in cardiac and liver injuries.

Journal: Cellular & molecular immunology

Published: August 14, 2025

Sphingolipid synthesis in tumor-associated macrophages confers immunotherapy resistance in hepatocellular carcinoma.

Sphingolipid synthesis in tumor-associated macrophages confers immunotherapy resistance in hepatocellular carcinoma.

Journal: Science advances

Published: May 21, 2025

Lactate metabolism reprogramming in PDAC: Potential for tumor therapy.

Lactate metabolism reprogramming in PDAC: Potential for tumor therapy.

Journal: Biochimica et biophysica acta. Reviews on cancer

Published: February 18, 2025

[18F]FAPI- 04 PET/CT for pathologic response assessment in pancreatic cancer patients with systemic treatment.

[18F]FAPI- 04 PET/CT for pathologic response assessment in pancreatic cancer patients with systemic treatment.

Journal: European journal of nuclear medicine and molecular imaging

Published: January 28, 2025

Targeting spermine metabolism to overcome immunotherapy resistance in pancreatic cancer.

Targeting spermine metabolism to overcome immunotherapy resistance in pancreatic cancer.

Journal: Nature communications

Published: November 26, 2024

Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma.

Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma.

Journal: The Journal of clinical investigation

Published: September 12, 2024

Lipid metabolism reprograming by SREBP1-PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy.

Lipid metabolism reprograming by SREBP1-PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy.

Journal: Cancer communications (London, England)

Published: June 10, 2024

Reprograming immunosuppressive microenvironment by eIF4G1 targeting to eradicate pancreatic ductal adenocarcinoma.

Reprograming immunosuppressive microenvironment by eIF4G1 targeting to eradicate pancreatic ductal adenocarcinoma.

Journal: Cell reports. Medicine

Published: February 16, 2024

Targeting cancer-associated fibroblast autophagy renders pancreatic cancer eradicable with immunochemotherapy by inhibiting adaptive immune resistance.

Targeting cancer-associated fibroblast autophagy renders pancreatic cancer eradicable with immunochemotherapy by inhibiting adaptive immune resistance.

Journal: Autophagy

Published: January 04, 2024

ALYREF-JunD-SLC7A5 axis promotes pancreatic ductal adenocarcinoma progression through epitranscriptome-metabolism reprogramming and immune evasion.

ALYREF-JunD-SLC7A5 axis promotes pancreatic ductal adenocarcinoma progression through epitranscriptome-metabolism reprogramming and immune evasion.

Journal: Cell death discovery

Published: November 03, 2023

Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy.

Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: April 26, 2023

Targeting MFAP5 in cancer-associated fibroblasts sensitizes pancreatic cancer to PD-L1-based immunochemotherapy via remodeling the matrix.

Targeting MFAP5 in cancer-associated fibroblasts sensitizes pancreatic cancer to PD-L1-based immunochemotherapy via remodeling the matrix.

Journal: Oncogene

Published: November 25, 2022

Showing 1-12 of 18

Last Updated: 09/26/2026